Accrol Share Discussion Threads

[this_is_me] 02/9/2021 12:31

Still going up with no sign of a pullback.

[ptolemy] 26/8/2021 10:28

I see Accrol is tipped in Shares Magazine.

[this_is_me] 26/8/2021 08:30

The share price continues to drift steadily upwards.

[haroldthegreat] 08/8/2021 12:18

Before getting too enthusiastic about panda look at comments on line re blocking pipes .
Of course there might be other causes for the blockage but I remember years ago reading about the problem with another brand .
As a prospective shareholder here i decided to try their product before buying the shares ,having avoided buying own brands before ,after my clinical trial i decided to change and although the share price dropped it has been compensated by the savings on andrex . After evil tipped these shares i purchased more
However.his tip on France to win the Euro was rubbish ! I only put £5 on it !

[stevesham] 28/7/2021 14:38

Link below to interview with Cheeky Panda



Just for information really as I still think Accrol are going places particularly with the new mill, but need to keep an eye on what is happening to their market

[stevesham] 28/7/2021 14:31

The future of tissue possibly and a competitor for Accrol maybe



The above may not work, but can register for free




Fastest growing plant on the planet quite a success story and IPO soon, will I hold both Accrol and this when it lists?

[simon gordon] 25/7/2021 16:28

Good to see in the recent Zeus note that the paper mill will be self funded and operational FY 2024. Looks like it's full steam ahead with internally generated organic growth.

"The paper mill development has also continued apace, with a full update expected once plans progress. However, Accrol intends to build a machine that will be a UK leader in efficiency, quality and carbon neutrality. No additional funding is expected to be required from shareholders to deliver this investment."

Zeus - 14/7/21

[masurenguy] 23/7/2021 16:30

Good to see some significant insider share buys. Should also silence the two resident trolls for awhile !

[stevieweebie2] 23/7/2021 16:23

yes
I just topped up on the back of it.

[mfhmfh] 23/7/2021 16:14

Chairman purchase

[ygor705] 22/7/2021 18:31

Very chunky sales late yesterday and today.

[ygor705] 22/7/2021 18:30

Consensus brokers consensus for normalised eps is 4.43p to 30 April 2022 and 5.16p for following year. That's against 0.17p to 30 Apr 2021. Stockopedia figures.

[bb123] 21/7/2021 10:23

Any comments on the full-year 2021 results presentation?

Do we have any BROKER FORECASTS for Accrol?

[tomps2] 21/7/2021 08:35

Accrol (ACRL) full-year 2021 results presentation

The full management team Dan Wright, Executive Chairman, Gareth Jenkins, CEO, Richard Newman, CFO and Graham Cox, Commercial Director give a comprehensive overview of the turnaround to date.

Watch the video here:

Or listen to the podcast here:

[tomps2] 15/7/2021 08:24

Accrol Group Holdings (ACRL) full-year 2021 results webinar, today (15/07/21) at 1:15pm

As part of the Group’s Financial Results roadshow, Dan Wright, Executive Chairman and Gareth Jenkins, CEO will present full year results followed by Q&A.

Register here:

[zipstuck] 14/7/2021 09:24

Acquisitions & Integrations

Following the acquisition of LTC in November 2020, we have completed the integration of the business and expect to deliver annualised synergy benefits of GBP3.0m - three times greater than originally anticipated at the time of the acquisition. These are being driven through operational improvements across the wider group, including logistics, operational simplification, and procurement. The revenue synergies, which are measured over an agreed period of time, will be lower during this Period, due to the impact of the pandemic, but are expected to benefit the Group in the longer term

In April 2021, the Group acquired the JD business in North Wales, a highly scalable flushable and bio-degradable wet wipe business. Early integration activities have progressed ahead of schedule and initial synergies are expected to be cGBP1m in the first full year of ownership. These will be delivered through operational synergies with the Group's existing facial tissue business, procurement benefits of the enlarged Group, simplification of organisation, and revenue growth opportunities, as the product offering to Accrol's existing customer base now includes its range of wet wipes. The Group's expectation with additional capital investment is to build a wet wipe business of significant scale by 2024.

[ygor705] 14/7/2021 08:29

The numbers are ahead of consensus forecasts so I would not expect the share price to come to much harm from here. The manufacturing side of the business looks to be moving towards complete automation by 2023 and distortions to the demand for tissue paper are steadily working there way out of the system. Firm hold for me.

[value viper] 14/7/2021 08:13

Directors to buy now results outI would think so (need to)

[bookbroker] 14/7/2021 07:57

What a load of waffle, ‘anticipated recovery’!

[masurenguy] 14/7/2021 07:54

Positive results statement !

"Despite the challenges of the pandemic, the Group was able to deliver on its strategic objectives. The business was successfully scaled, through the acquisition of Leicester Tissue Company and diversified via the John Dale wet wipes acquisition.

The team's continued focus on operational efficiency delivered an overall improvement in reported gross margin of 580ppt to 27.7% and a tripling of initial expectations on LTC synergies. Adjusted EBITDA rose by 47% in the year to £15.6m. Despite the volatility created in the tissue market by the pandemic limiting the Group's revenue growth to 1.4% in the Period, Accrol outperformed its peers and increased its market share to 15.9% from 13.1% in FY21. Over the last 2 years the like for like sales (excluding Away from Home) have grown by 16% from £117.6m to £136.6m and market share growth for the Group has risen from 12% to 15.9%. With the business in excellent operational shape, scalable foundations for growth in place, and a strong market position, the Group is very well placed to benefit from the anticipated recovery in tissue volumes, as the effects of the pandemic unwind.

The Group expects to see FY22 exit run rates to be significantly improved with the major discounters expecting uplift in tissue volumes and Accrol's recently secured additional new business has increased confidence for FY23 revenues and returns. Trading in line with forecasts in FY22 to date and the Board remains confident in the long-term prospects for Accrol"

[leadersoffice] 14/7/2021 07:09

Dividend restored 0.5p

[value viper] 13/7/2021 14:23

My gut feel - a buy now alsoWe will have to wait and see

[investorsiba] 13/7/2021 10:43

Still they sell, day before a trading update

My short has this back at 30p before too long imo